[Effect of the protease inhibitor aprotinin on pulmonary function and on the inhibitory activity of sputum in patients with chronic obstructive bronchitis].
It has been investigated whether a substitution of protease inhibitor deficiency is indicated in case of chronic obstructive airway disease. As a therapeutic possibility, apronitin isolated from bovine organs (tyasylol), which in vitro inhibits sputum proteases up to 80 per cent was tested. Besides infusion, inhalation was chosen for application by which a protease inhibition could be attained. We observed an inhibition of the course of illness associated with a good tolerance of the preparation. Whether a therapy applying the addition of protease inhibitor is reasonable in the long run in chronic diseases cannot yet be concluded from these investigations.
D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D007611:Aprotinin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000503:physiopathology*; D002908:Chronic Disease; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D008168:Lung / Q000503:physiopathology; D008875:Middle Aged; D010993:Plethysmography, Whole Body; D012138:Respiratory Therapy; D013183:Sputum / Q000187:drug effects / Q000201:enzymology*
D000336:Aerosols; D007611:Aprotinin
Uber die Wirkung des Proteaseinhibitors Aprotinin auf die Lungenfunktion sowie die inhibitorische Aktivatt des Sputums bei Patienten mit chronisch-obstruktiver Bronchitis